Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIO OTCMKTS:EVTCY NASDAQ:GBT NASDAQ:NKTR NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$51.49+0.0%$48.70$21.72▼$54.60$9.84B1.252.94 million shs2.43 million shsEVTCYEvotec$3.50+0.9%$3.81$14.22▼$26.57$1.16B0.982,407 shs24,231 shsGBTGlobal Blood Therapeutics$68.49$68.47$21.65▼$73.02$4.62B0.452.07 million shs74 shsNKTRNektar Therapeutics$49.89+1.8%$28.53$6.45▼$50.53$948.91M1.05894,365 shs1.50 million shsUTHRUnited Therapeutics$397.97-1.3%$320.79$266.98▼$436.95$17.95B0.62565,499 shs485,489 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma+0.51%-5.19%+0.29%+28.45%+96.60%EVTCYEvotec0.00%-0.29%-7.71%-15.98%-1.98%GBTGlobal Blood Therapeutics0.00%0.00%0.00%0.00%0.00%NKTRNektar Therapeutics+0.68%+10.56%+79.79%+461.40%+149.41%UTHRUnited Therapeutics-0.47%+2.15%+28.74%+40.52%+18.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$51.49+0.0%$48.70$21.72▼$54.60$9.84B1.252.94 million shs2.43 million shsEVTCYEvotec$3.50+0.9%$3.81$14.22▼$26.57$1.16B0.982,407 shs24,231 shsGBTGlobal Blood Therapeutics$68.49$68.47$21.65▼$73.02$4.62B0.452.07 million shs74 shsNKTRNektar Therapeutics$49.89+1.8%$28.53$6.45▼$50.53$948.91M1.05894,365 shs1.50 million shsUTHRUnited Therapeutics$397.97-1.3%$320.79$266.98▼$436.95$17.95B0.62565,499 shs485,489 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma+0.51%-5.19%+0.29%+28.45%+96.60%EVTCYEvotec0.00%-0.29%-7.71%-15.98%-1.98%GBTGlobal Blood Therapeutics0.00%0.00%0.00%0.00%0.00%NKTRNektar Therapeutics+0.68%+10.56%+79.79%+461.40%+149.41%UTHRUnited Therapeutics-0.47%+2.15%+28.74%+40.52%+18.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 3.00Buy$63.9424.89% UpsideEVTCYEvotec 0.00N/AN/AN/AGBTGlobal Blood Therapeutics 0.00N/AN/AN/ANKTRNektar Therapeutics 2.86Moderate Buy$88.3377.22% UpsideUTHRUnited Therapeutics 2.69Moderate Buy$438.859.74% UpsideCurrent Analyst Ratings BreakdownLatest UTHR, GBT, BBIO, NKTR, and EVTCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025BBIOBridgeBio PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.009/12/2025BBIOBridgeBio PharmaUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$72.00 ➝ $82.009/10/2025UTHRUnited TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$405.00 ➝ $525.009/5/2025UTHRUnited TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$510.00 ➝ $575.009/5/2025UTHRUnited TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$400.00 ➝ $500.009/4/2025UTHRUnited TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$415.00 ➝ $560.009/3/2025BBIOBridgeBio PharmaJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$55.00 ➝ $70.009/3/2025UTHRUnited TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$295.00 ➝ $414.009/2/2025UTHRUnited TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$432.00 ➝ $564.009/2/2025UTHRUnited TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$314.00 ➝ $463.008/29/2025BBIOBridgeBio PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $70.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$235.81M41.51N/AN/A($7.71) per share-6.64EVTCYEvotec$572.16M2.02$0.03 per share105.53$2.52 per share1.39GBTGlobal Blood Therapeutics$194.75M23.73N/AN/A$3.05 per share22.46NKTRNektar Therapeutics$98.43M9.63N/AN/A$4.94 per share10.09UTHRUnited Therapeutics$2.88B6.27$28.02 per share14.27$144.34 per share2.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$4.09N/AN/AN/A-329.25%N/A-85.69%11/11/2025 (Estimated)EVTCYEvotec$7.14M$0.418.54∞N/A20.85%16.02%7.81%N/AGBTGlobal Blood Therapeutics-$303.09M-$5.01N/AN/AN/A-137.30%-170.37%-39.24%N/ANKTRNektar Therapeutics-$118.96M-$8.80N/AN/AN/A-163.17%-631.43%-58.21%11/6/2025 (Estimated)UTHRUnited Therapeutics$1.20B$25.6215.6114.556.1740.36%18.73%16.49%10/29/2025 (Estimated)Latest UTHR, GBT, BBIO, NKTR, and EVTCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025NKTRNektar Therapeutics-$3.13-$2.95+$0.18-$2.95$9.42 million$11.18 million8/5/2025Q2 2025BBIOBridgeBio Pharma-$0.83-$0.95-$0.12-$0.95$98.46 million$110.57 million7/30/2025Q2 2025UTHRUnited Therapeutics$6.80$6.41-$0.39$6.41$802.13 million$798.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/AEVTCYEvotecN/AN/AN/AN/AN/AGBTGlobal Blood TherapeuticsN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A5.195.08EVTCYEvotec0.532.572.50GBTGlobal Blood Therapeutics4.926.886.17NKTRNektar TherapeuticsN/A2.612.61UTHRUnited TherapeuticsN/A7.266.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%EVTCYEvotecN/AGBTGlobal Blood TherapeuticsN/ANKTRNektar Therapeutics75.88%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%EVTCYEvotecN/AGBTGlobal Blood Therapeutics4.90%NKTRNektar Therapeutics3.71%UTHRUnited Therapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400191.17 million156.38 millionOptionableEVTCYEvotec4,200330.22 millionN/ANot OptionableGBTGlobal Blood Therapeutics45767.48 million64.17 millionOptionableNKTRNektar Therapeutics22019.02 million18.31 millionOptionableUTHRUnited Therapeutics1,30545.11 million40.46 millionOptionableUTHR, GBT, BBIO, NKTR, and EVTCY HeadlinesRecent News About These CompaniesLiquidia Corporation (LQDA): A Bull Case Theory2 hours ago | uk.finance.yahoo.comUnited Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare ForumSeptember 16 at 10:19 AM | pharmiweb.comPSwedbank AB Decreases Stock Position in United Therapeutics Corporation $UTHRSeptember 15 at 5:27 AM | marketbeat.comUnited Therapeutics Corporation $UTHR Shares Sold by Integrated Wealth Concepts LLCSeptember 15 at 3:30 AM | marketbeat.comUBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Purchases 25,289 Shares of United Therapeutics Corporation $UTHRSeptember 15 at 3:09 AM | marketbeat.comFY2025 EPS Estimates for UTHR Raised by Cantor FitzgeraldSeptember 14 at 6:34 AM | marketbeat.comInspire Investing LLC Sells 1,237 Shares of United Therapeutics Corporation $UTHRSeptember 14 at 5:56 AM | marketbeat.comUTHR FY2025 EPS Forecast Lifted by Cantor FitzgeraldSeptember 14 at 2:29 AM | americanbankingnews.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $1,588,920.00 in StockSeptember 13 at 8:34 PM | marketbeat.comFY2026 EPS Estimates for UTHR Increased by Cantor FitzgeraldSeptember 13 at 7:54 AM | marketbeat.comAcadian Asset Management LLC Acquires 169,010 Shares of United Therapeutics Corporation $UTHRSeptember 13 at 5:35 AM | marketbeat.comFred Alger Management LLC Makes New $256,000 Investment in United Therapeutics Corporation $UTHRSeptember 13 at 4:08 AM | marketbeat.comEquities Analysts Offer Predictions for UTHR FY2026 EarningsSeptember 13 at 2:43 AM | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Director Sells $280,203.00 in StockSeptember 12, 2025 | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells 4,560 Shares of StockSeptember 12, 2025 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) COO Sells $1,961,050.00 in StockSeptember 12, 2025 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 8,000 SharesSeptember 12, 2025 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) COO Sells $4,520,538.75 in StockSeptember 12, 2025 | marketbeat.comCantor Fitzgerald Issues Positive Forecast for United Therapeutics (NASDAQ:UTHR) Stock PriceSeptember 12, 2025 | marketbeat.com21,112 Shares in United Therapeutics Corporation $UTHR Acquired by Capital Impact Advisors LLCSeptember 12, 2025 | marketbeat.comMartine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) StockSeptember 12, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUTHR, GBT, BBIO, NKTR, and EVTCY Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$51.49 +0.02 (+0.04%) Closing price 04:00 PM EasternExtended Trading$50.96 -0.53 (-1.03%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Evotec OTCMKTS:EVTCY$3.50 +0.03 (+0.86%) As of 09/15/2025Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.Global Blood Therapeutics NASDAQ:GBTGlobal Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.Nektar Therapeutics NASDAQ:NKTR$49.89 +0.88 (+1.80%) Closing price 04:00 PM EasternExtended Trading$49.95 +0.06 (+0.12%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.United Therapeutics NASDAQ:UTHR$397.97 -5.14 (-1.28%) Closing price 04:00 PM EasternExtended Trading$388.00 -9.97 (-2.51%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
